| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
AIRWAY BIOLOGY |
1 Centre for Respiratory Research, Royal Free and University College London Medical School, London, UK
2 Department of Toxicology, University of Cagliari, Cagliari, Italy
3 Department of Pulmonary Medicine and Critical Care Medicine, Brigham and Women’s Hospital, Boston, USA
4 Department of Pharmacology, University College London, London, UK
Correspondence to:
Correspondence to:
Dr L Atzori
Centre for Respiratory Research, Royal Free and University College Medical School, 5 University Street, London WC1E 6JJ, UK; latzori{at}unica.it
ABSTRACT
Background: Pulmonary fibrosis is associated with a poor prognosis. The pathogenesis of fibrotic lung disorders remains unclear, but the extent of tissue damage due to the persistent presence of oxidants or proteases is believed to be important. The heme degrading enzyme heme oxygenase (HO) has been found to be expressed in experimental fibrosis, and generation of free iron and carbon monoxide (CO) by HO has been implicated in oxidant induced lung damage. A study was undertaken to examine the effects of the HO inhibitor Zn-deuteroporphyrin-IX-2,4-bisethylene glycol (Zndtp) on the development of pulmonary fibrosis in the bleomycin model of lung injury and repair.
Methods: Zndtp (10 µmol/kg) was administered subcutaneously twice daily to mice 1 week following the intratracheal instillation of 0.025 U bleomycin. Animals were killed 10 or 21 days after bleomycin instillation and indices of lung damage and fibrosis were evaluated.
Results: Bleomycin treatment induced pulmonary cytotoxicity, increased levels of active transforming growth factor ß (TGF-ß), enhanced lung collagen accumulation, and decreased glutathione content. Zndtp administration significantly attenuated these indices.
Conclusions: Administration of Zndtp in the bleomycin model resulted in appreciable alveolar cytoprotection and amelioration of pulmonary fibrosis. This molecule and its analogues may warrant further consideration in the treatment of acute lung injury and fibrotic lung disorders.
Keywords: bleomycin; lung fibrosis; Zn-deuteroporphyrin-IX-2,4-bisethylene glycol; heme oxygenase
Abbreviations: HO, heme oxygenase; LDH, lactate dehydrogenase; MAL, malondialdehyde; TGF-ß, transforming growth factor ß; Zndtp, Zn-deuteroporphyrin IX-2,4-bisethylene glycol
Relevant Article
Thorax 2004 59: 181.
This article has been cited by other articles:
|
|
 |
|
  Q. Ye, Y. Dalavanga, N. Poulakis, S. U. Sixt, J. Guzman, and U. Costabel Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis Eur. Respir. J., May 1, 2008; 31(5): 1030 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Fredenburgh, M. A. Perrella, and S. A. Mitsialis The Role of Heme Oxygenase-1 in Pulmonary Disease Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 158 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Ryter, J. Alam, and A. M. K. Choi Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications Physiol Rev, April 1, 2006; 86(2): 583 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Morse and A. M. K. Choi Heme Oxygenase-1: From Bench to Bedside Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 660 - 670. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
